Compare AbCellera Biologics Inc (ABCL) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Bank of Nova Scotia — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Bank of Nova Scotia trades at $84.92 (market cap $105.63B). The key difference: Bank of Nova Scotia is far larger — about 44.9× AbCellera Biologics Inc's market cap, and Bank of Nova Scotia pays a 3.83% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BNS | |
|---|---|---|
Market Cap | $2.35B | $105.63B |
Sector | Health | Financials |
52-Week High | $8.12 | $87.35 |
52-Week Low | $2.78 | $54.50 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BNS trades at $86.20, up 0.94% today, with strong technical momentum showing bullish moving averages and resistance near $88. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS expected at $1.51, while revenue grew to $37.10B in 2025. Recent news highlights dividend increases and strategic acquisitions like MapleMark Bank, reinforcing growth prospects in global markets.
Outlook remains positive with analyst consensus favoring Buy ratings (52.63%), though valuation multiples like P/E of 17.05 warrant monitoring. Key risks include economic sensitivity and debt levels, but robust cash flow and dividend yield support income-focused investors. Upside depends on execution of growth initiatives and sustained earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
